Vitreomacular traction (VMT) syndrome is a potentially visually significant disorder of the vitreoretinal interface characterized by an incomplete posterior vitreous detachment with the persistently adherent vitreous exerting tractional pull on the macula and resulting in morphologic alterations and consequent decline of visual function.

The resulting condition is called vitreomacular traction (VMT) syndrome. VMT syndrome can lead to different maculopathies or disorders in the macular area (at the center of the retina), such as full- or partial-thickness macular holes , epiretinal membranes , and cystoid macular edema .

Aug 27, 2024 · Vitreomacular traction (VMT) occurs when vitreous in the aging eye doesn’t detach completely from the macula. VMT can cause vision loss if left untreated.

Jan 20, 2025 · Vitreomacular traction (VMT) is characterised by abnormal adhesion of the posterior cortical vitreous with the macula causing distortion of the foveal contour and associated with symptoms of...

In cases of VMT, treatment with ocriplasmin is indicated when traction is ≤1500 μm and in the absence of concurrent macular diseases (ERM). In the case of MH, the hole diameter should be ≤400, traction has to be present, and ERM should be absent.

VMT syndrome is most common in older adults and women due to age-related vitreous changes and vitreous liquefaction associated with declining post-menopausal estrogen levels, respectively. • Other risk factors include: • High myopia (extreme nearsightedness) • Exudative (wet) age-related macular degeneration • Diabetic macular edema

In VMT, raised edges of adherent vitreous may be seen in a peripapillary distribution around the optic nerve head and is referred to as vitreopapillary traction. This condition can be confused with optic nerve disorders such as papilledema.

Treatment of VMT and Holes Jetrea (Ocriplasmin) • Alpha-2 antiplasmin reducer • Produces proteolytic activity against protein components within the vitreous body and vitreoretinal interface (laminin, fibronectin, collagen) • FDA approved in 2012 as treatment for VMT • Dosage 0.125 mg

Vitreomacular traction (VMT) syndrome is an eye condition involving the vitreous, the clear gel that fills the within the eyeball. It is a vision-threatening condition and can cause symptoms varying from lowered and blurred vision to distorted and blacked-out main vision.

There are instances where a PVD is incomplete, leaving the vitreous partially attached to the retina, and causing tractional (pulling) forces that can cause anatomical damage. The resulting condition is called vitreomacular traction (VMT) syndrome.